Document is current
Any future updates will be listed below
-
Authors
Cuglievan, Branko http://orcid.org/0000-0002-6917-2244
Kantarjian, Hagop http://orcid.org/0000-0002-1908-3307
Rubnitz, Jeffrey E.
Cooper, Todd M.
Zwaan, C. Michel
Pollard, Jessica A.
DiNardo, Courtney D. http://orcid.org/0000-0001-9003-0390
Kadia, Tapan M. http://orcid.org/0000-0002-9892-9832
Guest, Erin http://orcid.org/0000-0003-2482-5608
Short, Nicholas J. http://orcid.org/0000-0002-2983-2738
McCall, David http://orcid.org/0000-0003-2297-9670
Daver, Naval http://orcid.org/0000-0001-7103-373X
Nunez, Cesar
Haddad, Fadi G.
Garcia, Miriam http://orcid.org/0000-0002-2978-2267
Bhalla, Kapil N. http://orcid.org/0000-0001-5209-5126
Maiti, Abhishek
Catueno, Samanta http://orcid.org/0000-0002-0072-8603
Fiskus, Warren http://orcid.org/0000-0002-7343-6214
Carter, Bing Z. http://orcid.org/0000-0003-0076-0889
Gibson, Amber
Roth, Michael
Khazal, Sajad
Tewari, Priti
Abbas, Hussein A. http://orcid.org/0000-0003-2946-3562
Bourgeois, Wallace
Andreeff, Michael http://orcid.org/0000-0002-1144-1958
Shukla, Neerav N.
Truong, Danh D.
Connors, Jeremy http://orcid.org/0000-0003-2817-8890
Ludwig, Joseph A. http://orcid.org/0000-0001-6631-8554
Stutterheim, Janine http://orcid.org/0000-0002-9828-0834
Salzer, Elisabeth http://orcid.org/0000-0002-8118-4934
Juul-Dam, Kristian L.
Sasaki, Koji http://orcid.org/0000-0002-9140-0610
Mahadeo, Kris M.
Tasian, Sarah K. http://orcid.org/0000-0003-1327-1662
Borthakur, Gautam http://orcid.org/0000-0001-7679-6453
Dickson, Samantha
Jain, Nitin
Jabbour, Elias http://orcid.org/0000-0003-4465-6119
Meshinchi, Soheil
Garcia-Manero, Guillermo http://orcid.org/0000-0002-3631-2482
Ravandi, Farhad http://orcid.org/0000-0002-7621-377X
Stein, Eytan M.
Kolb, E. Anders
Issa, Ghayas C. http://orcid.org/0000-0002-4339-8683
- License Information
-
More Information
Article History
Received: 4 June 2024
Revised: 23 July 2024
Accepted: 29 July 2024
First Online: 23 August 2024
Competing interests
: C. Michel Zwaan: Receives research funding from AbbVie, BMS, Gilead, Kura Oncology, Novartis, Pfizer, Syndax, and Takeda. Engages in consultancy for BMS, Gilead, and Novartis. - Ghayas Issa: Receives consultancy and research funding from Astex, Celgene, Kura Oncology, Merck, Novartis, NuProbe, and Syndax. - BC: Receives research funding from Astex, Kura Oncology, LLS, Octapharma, and Syndax. - David McCall: Receives research funding from Kura Oncology. - MG: Receives research funding from Cellestia. - AG: Receives research funding from Astex. - NNS: Serves on the board of directors or advisory committees for Syndax. - EMS: Receives research funding from Bristol Myers Squibb, Eisai, and Novartis. Engages in consultancy for Agios, Astellas, Bristol Myers Squibb, Daiichi, Foghorn, Genentech, Gilead, Janssen, Jazz, Menarini, Neoleukin, Novartis, OnCusp, Pfizer, PinotBio, Servier, Syndax, and Takeda. - EJ: Engages in consultancy and receives honoraria and research funding from AbbVie, Adaptive Biotech, Amgen, Ascentage Pharma Group, Astellas, Astex, Bristol-Myers Squibb, Genentech, Hikma Pharmaceuticals, Novartis, Pfizer, and Takeda. - NJ: Engages in consultancy and receives honoraria, travel support, and research funding from AbbVie, Adaptive Biotechnologies, ADC Therapeutics, Aprea Therapeutics, Ascentage Pharma Group, AstraZeneca, Beigene, BMS, Cellectis, Dialectic Therapeutics, Fate Therapeutics, Genentech, Ipsen, Janssen, Kite/Gilead, Loxo Oncology, MEI Pharma, Medisix, Mingsight, Novalgen, Pharmacyclics, Precision Biosciences, Syros, TG Therapeutics, and TransThera Sciences. - FR: Engages in consultancy and receives honoraria and research funding from Abbvie, Amgen, Astex/taiho, Astellas, Biomea fusion, Celgene/BMS, Prelude, Syros, and Xencor. - AM: Receives research funding from Celgene and Lin BioScience. - ND: Engages in consultancy and receives research funding from Agios, Amgen, AROG, Astellas, Bristol-Myers Squibb, Daiichi Sankyo, FATE, Gilead, Hanmi, ImmunoGen, Janssen, Jazz, Novartis, Pfizer, Sanofi-Aventis, Servier, Syndax, Trillium, Trovagene, and Kite (a Gilead company). - CDD: Receives honoraria from AbbVie/Genentech, Astellas, BMS, Fogham, Notable Labs, Novartis, Schrödinger, Servier, and Takeda. Engages in consultancy for ImmuniOnc and Schrödinger. - TMK: Receives speakers bureau fees from Hikma Pharmaceuticals and research funding from AstraZeneca, Astellas Pharma Global Development, Ascentage Pharma Group, Cellenkos Inc., Celgene, Cyclacel, GenFleet Therapeutics, Genentech, Glycomimetics, Iterion, Jazz Pharmaceuticals, and Pfizer. - NJS: Engages in consultancy and receives research funding from Astellas, AstraZeneca, Novartis, Pfizer, Stemline Therapeutics, and Takeda. Also receives honoraria from Amgen and consultancy from Pfizer. - GB: Serves on the board of directors or advisory committees for Bio Ascend, Cytomx, Novartis, and Pacylex. Receives research funding from Astex Pharmaceuticals, PTC Therapeutics, Ryvu, and consultancy fees from Abbvie, Catamaran Bio, Janssen, Protagonist Therapeutics, and PPD Development. - HK: Receives research funding from AbbVie, Actinium, Amgen, Astex, BMS, Cyclacel, Daiichi-Sankyo, Gilead, Immunogen, Jazz Pharma, Novartis, Orsinex, Pfizer, and Takeda. - GG-M: Receives research funding from AbbVie, Bristol Myers Squibb, and Genentech. - MA: Receives research funding from Kintor Pharmaceutical and PMV. - KNB: Receives research funding from Foghorn Therapeutics Inc. - SKT: Receives research funding from Beam Therapeutics, Incyte Corporation, and Kura Oncology. Serves on scientific advisory boards for Aleta Biotherapeutics, Astra Zeneca, Jazz Pharmaceuticals, Kura Oncology, and Syndax Pharmaceuticals. Receives travel support from Amgen. SKT is a Scholar of the Leukemia & Lymphoma Society and holds the Joshua Kahan Endowed Chair in Pediatric Leukemia Research at the Children’s Hospital of Philadelphia - HAA: Receives research funding from Genentech, Illumina, and Molecular Partners. Engages in consultancy for Gilead. - KMM: Receives honoraria and research funding from Jazz. - JER: Engages in consultancy for Biomea, Inc. - JAP: Receives research funding from Abbvie and Servier.
